Respiree

News

Health tech Respiree, developer of AI platforms to manage disease progression, has announced the successful closing of an $11.6m Series A financing.

News

The real-time sensor can be used to spot exacerbations of COPD days in advance, says company.

News

Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.